What Clinics Ask Before Ordering Wharton's Jelly Products: A Supplier Checklist

Start with donor sourcing and screening, not the product spec sheet

Wharton's jelly is the gelatinous connective tissue of the umbilical cord. Before comparing vial sizes or formats, ask how the supplier sources the tissue: donation should occur at the time of a scheduled, full-term C-section delivery with consenting donors, and donors should be screened through medical and social history review plus serology testing for communicable disease.

Ask whether donation affects a mother's ability to also bank cord blood. A supplier that has thought through donor consent and the broader donation process usually has an organized answer to this; a vague answer is itself useful information.

Ask how the tissue was processed and tested, lot by lot

Processing time matters: ask how soon after recovery the tissue is processed, and ask the supplier to describe specifically which regulations and guidelines its processing follows, for example FDA regulations and AATB or AABB guidelines. 'Described as following' is a different claim than 'certified by,' and clinics should know which one they are getting.

Every lot should carry a unique lot identifier, and samples from each lot should go to a third-party laboratory for sterility testing before the lot is released from quarantine. Ask to see a certificate of analysis and a donor eligibility summary for a sample lot before you order, not just after.

Separate format questions from composition claims

Formats differ by intended use case: an off-the-shelf, ready-to-use scaffold format, higher-concentration formats in smaller vial sizes, and lyophilized formats that do not require cryogenic storage. None of these format differences change what is or is not documented about cell content.

Independent analyses of commercial umbilical cord allograft products have generally found low total cell counts and little to no colony-forming mesenchymal stem cell activity across brands. That is a reason to ask for the specific composition data behind a given lot rather than accept 'stem cell' language as a description of what is in the vial.

Questions that belong on every intake call

A short list of direct questions resolves most sourcing, processing, and documentation gaps before the first order ships.

• Can you provide a certificate of analysis and donor eligibility summary for a representative lot?
• What is your processing timeline from recovery to release, and what guidelines do you describe your processing as following?
• How is each lot's sterility testing performed, and by whom?
• What storage and shipping conditions apply to this specific format, and is that written in the product insert?
• Whose determination is it that our intended use qualifies under section 361 of the HCT/P framework for our specific case?
• Do you require NPI verification to open an account, and how is pricing handled for verified accounts?